RxDoctor Payments DataLook up a doctor →

Gerard Criner, MD

Pulmonary Disease · Philadelphia, PANPI 1013905157

Payments from drug & device makers

$18,228,496in general payments, 2019–2025

Across 1,701 payments — averaging $10,716 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fisher & Paykel Healthcare Limited$4.5M
  • Regeneron$2.4M
  • Boehringer Ingelheim$2.3M
  • Gilead$2.1M
  • GSK$1.2M
  • Pleural Dynamics Inc.$982K
  • plus $4.7M from 47 others
$69,328in research payments, 2019–2025

Across 10 payments — averaging $6932.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$43K
  • Philips North America LLC$20K
  • Novartis$3K
  • Regeneron$2K
  • Medtronic$1K

What the payments were for

  • Consulting fees$424,71965%
  • Speaking & faculty fees$48,2897%
  • Grants$22,6203%
  • Travel & lodging$83,36613%
  • Food & beverage$6,9041%
  • Education$70,84011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,228,496 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$643,481
Medicare patients
684
Services billed
11,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate176$1,832,392
OpsumitMacitentan12$153,841
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$137,833
Trelegy ElliptaFluticasone/Umeclidin/Vilanter154$134,101
FasenraBenralizumab17$92,707
XolairOmalizumab24$82,202
Dupixent PenDupilumab16$59,759
NucalaMepolizumab14$51,087
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$42,738
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$32,119
Atovaquone48$28,458
Breo ElliptaFluticasone/Vilanterol29$15,114
Spiriva HandihalerTiotropium Bromide25$13,819
Incruse ElliptaUmeclidinium Bromide32$10,253
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$7,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$2,269,678$1,839,472187 claims
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,240,995$242,673282 claims
AstraZenecaFasenra, Breztri Aerosphere, Symbicort$577,300$142,01798 claims
Genentech, Inc.Xolair$398,041$82,20224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →